Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320

LAURUS Labs
Knowledge . Innovation . Excellence

September 18, 2019

To	To
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 **Code: 540222**	The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 **Code: LAURUSLABS**

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform you that Laurus Labs Limited has agreed to acquire 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary company of Pharmacare Limited t/a Aspen Pharmacare, South Africa, subject to completion of conditions precedent, by way of cash consideration of ZAR 75,000 (Seventy-five thousand South African Rand).

At the conclusion of the transaction, all residual assets and liabilities that are within the target company immediately prior to completion will be for Pharmacare Limited's account and accordingly all such assets and liabilities will be transferred from the target company to Pharmacare Limited immediately prior to completion.

This transaction will provide Laurus access to the South African public antiretroviral ("ARV") sector, which manages the world's largest public ARV programme. While Aspen will continue to manufacture the finished dose form ARV's for the South African public sector, the supply to this sector will be through Laurus' newly acquired South African subsidiary.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, is attached as per 'Annexure A'.

This is for your information and record.

Yours faithfully,
For Laurus Labs Ltd

LAURUS LABS LIMITED Hyderabad

G. Venkateswar Reddy
Company Secretary

Encl: as above

Annexure-A

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Name of the Company: Phekolong Pharmaceuticals Pty Ltd Turnover: FY 2019 – ZAR 20 mn
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No; Not a Related Party Transaction Promoter/ Promoter Group/ Group Companies have no interest in the entity being acquired.
c) Industry to which the entity being acquired belongs;	Pharmaceutical
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To get entry into the public market of South Africa
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental approvals required in India; But Governmental approvals are required in South Africa
f) Indicative time period for completion of the acquisition;	November 2019 subject to completion of Conditions Precedent
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration
h) Cost of acquisition or the price at which the shares are acquired;	ZAR 75,000 (Seventy-five thousand South African Rands only)
i) Percentage of shareholding / control acquired and / or number of shares acquired;	100% shareholding (2000 ordinary shares)
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The purpose of the acquisition is to gain entry to the public market in South Africa. As such, we have entered into a strategic partnership with Aspen Pharmacare to acquire a fully owned subsidiary holding the required licenses to enable us to participate in this market. We have further entered into a License and Distribution agreement as well as a Toll Manufacturing agreement with Aspen Pharmacare to enable our strategy and entry into this market. Date of Incorporation: 20th June 1979 Last three years' turnover: 2019 – ZAR 20 m 2018 – ZAR 20.5 m 2017 – ZAR 115,3 m Country in which the acquired entity has presence : South Africa

LAURUS LABS LIMITED Hyderabad